Transcriptomics

Dataset Information

0

Aldehydes alter TGF-β signaling and induce obesity and cancer


ABSTRACT: Obesity and fatty liver diseases-metabolic dysfunction-associated steatotic liver disease (MASLD and MASH) affect over a third of the global population and are exacerbated in individuals with reduced functional aldehyde dehydrogenase 2 (ALDH2), observed in approximately 560 million people. Current treatment to prevent disease progression to cancer remains inadequate, requiring innovative approaches. We observe that Aldh2-/- and Aldh2-/-Sptbn1+/- (ASKO) mice develop phenotypes of human Metabolic Syndrome (MetS) and MASH with altered lipid metabolism and TGF-β signaling, leading to pro-fibrotic and pro-oncogenic phenotypes, which is restored to normal with siRNA to SPTBN1. Significantly, therapeutic inhibition of SPTBN1 blocks MASH and fibrosis in a human 3D MASH model. This study identifies SPTBN1 as a critical regulator of the functional phenotype of toxic aldehyde-induced MASH and a potential therapeutic target.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE273561 | GEO | 2024/08/06

REPOSITORIES: GEO

Similar Datasets

2023-12-22 | GSE251855 | GEO
2024-06-17 | GSE246221 | GEO
2024-08-30 | GSE247407 | GEO
2024-06-07 | MSV000094959 | MassIVE
2024-09-12 | GSE254841 | GEO
2024-07-23 | GSE261088 | GEO
2024-09-03 | GSE274914 | GEO
2021-03-25 | GSE169586 | GEO
2024-05-17 | GSE240729 | GEO
2023-04-16 | MSV000091724 | MassIVE